ContactDictionary

Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  neratinib
Find trials that include:  Any drugs shown
Results 1-11 of 11 for your search:
Start Over
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PUMA-NER-1301, NCI-2013-01418, 2012-004492-38, UTN U1111-1161-1603, NCT01808573
A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NSABP FB-10, NCI-2015-00275, NCT02236000
Neratinib in Treating Pediatric Patients with Recurrent or Refractory Solid Tumors or Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 to 21
Trial IDs: 16-878, NCI-2016-01571, NCT02932280
Neratinib and Paclitaxel with or without Pertuzumab and Trastuzumab before Combination Chemotherapy in Treating Patients with Metastatic or Locally Advanced Breast Cancer
Status: Not yet active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2016-0537, NCI-2017-00813, NCT03101748
I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 097517, NCI-2015-00014, NCT01042379
Neratinib, Capecitabine, and Trastuzumab in Treating Patients with HER2-Positive Breast Cancer That Has Spread to the Brain
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-344, NCI-2012-00255, TBCRC 022, NCT01494662
Neratinib with or without Fulvestrant in Metastatic HER2-Negative but HER2 Mutant Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 201209135, NCI-2012-01513, NCT01670877
An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PUMA-NER-5201, NCI-2014-00495, 2013-002872-42, NCT01953926
A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: PUMA-NER-6201, NCI-2015-00769, NCT02400476
Neratinib in Treating Older Patients with Stage IV HER2-Positive Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: 15342, NCI-2015-02282, NCT02673398
Abemaciclib, DNA-PK/TOR Kinase Inhibitor CC-115, or Neratinib in Treating Patients with Brain Tumors after Biomarker Screening
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-443, NCI-2017-00433, NCT02977780
Start Over